8-K/A: ABVC BioPharma: Auditor Refuses SEC Letter on Non-Renewal

ABVC BioPharma discloses that its former independent auditor, WWC, P.C., has refused to provide a letter to the SEC regarding its non-renewal of engagement.

Summary

• ABVC BioPharma, Inc. filed an amendment (Form 8-K/A) to its Current Report on Form 8-K.
• The original 8-K, filed on October 18, 2024, disclosed that WWC, P.C., the company's independent registered public accounting firm, agreed not to renew its engagement with the company on October 10, 2024.
• The amendment, dated September 12, 2025, states that WWC, P.C. has refused to provide a letter to the Securities and Exchange Commission agreeing or disagreeing with the statements made in the original 8-K, despite being requested to do so.

Sentiment

Score: 3

Explanation: The refusal of the former auditor to provide a customary letter to the SEC is a negative signal, potentially indicating underlying issues or disagreements that could impact investor confidence and regulatory scrutiny. This is generally viewed as an unfavorable development.

Negatives

• The company's former independent auditor, WWC, P.C., has refused to provide a customary letter to the SEC confirming or disagreeing with the company's statements regarding the non-renewal of its engagement, which could raise questions about the circumstances of the auditor change.

Risks

• The refusal of the former auditor to provide a customary letter to the SEC could signal potential disagreements or unresolved issues, potentially impacting investor confidence and increasing regulatory scrutiny.
• This situation may complicate the process of securing a new auditor or could lead to delays in future financial filings if the auditor change process is not transparent and fully resolved.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding the company's operations or financial performance.

Management Comments

• "We filed a Current Report on Form 8-K on October 18, 2024, to disclose that on October 10, 2024, WWC, P.C. (WWC), serving as the Company's independent registered public accounting firm, agreed not to renew its engagement with the Company."
• "As disclosed in the Original 8K, although we provided WWC with a copy of the Original 8K and requested WWC to furnish us with a letter addressed to the Securities and Exchange Commission stating whether it agrees with the statements made therein, WWC had not yet agreed or declined to provide such a letter."
• "As of the date hereof, WWC has refused to provide us with such a letter."

Industry Context

Changes in independent auditors are a routine part of corporate governance, but a refusal by a former auditor to provide a customary letter to the SEC can be viewed negatively by the market. This situation may raise concerns about the transparency and integrity of financial reporting, particularly in the biotech/pharma sector where investor confidence in disclosures is paramount.

Comparison to Industry Standards

• Industry best practice for auditor changes typically involves the former auditor providing a letter to the SEC stating whether they agree with the company's disclosures regarding the change, as required by Item 304(a)(3) of Regulation S-K.
• The refusal by WWC, P.C. to provide such a letter deviates from this standard practice, which could be interpreted as a red flag by investors and regulators, suggesting potential unresolved issues or disagreements.

Corporate Governance

Stakeholder Impact

• Shareholders: May face increased uncertainty and potential erosion of confidence due to the auditor's refusal to cooperate with SEC disclosure requirements, potentially impacting share price.
• Regulators (SEC): Likely to scrutinize the circumstances surrounding the auditor change and the refusal to provide a letter, potentially leading to further inquiries.

Key Dates

Recommendation

The refusal of a former independent auditor to provide a customary letter to the SEC regarding its non-renewal is a significant red flag. This action suggests potential unresolved disagreements or undisclosed issues, which can severely undermine investor confidence in the company's financial reporting and corporate governance. Such an event typically leads to increased regulatory scrutiny and negative market sentiment, making the stock a high-risk investment with potential for downward pressure.

Keywords

ABVC BioPharma, WWC P.C., Auditor Change, SEC Filing, 8-K/A, Independent Accountant, Corporate Governance, Financial Reporting